Gregory Chow Biography and Net Worth

Chief Financial Officer of Sutro Biopharma

Greg Chow, M.B.A., has served as the Chief Financial Officer of Sutro since June 2025, bringing more than 25 years of experience across corporate finance, capital markets, drug development operations, and business development.

Prior to joining Sutro, Greg served as Chief Financial Officer and Chief Business Officer at NodThera, and previously held Chief Financial Officer roles at Freenome Holdings, Inc., Frontier Medicines Corp., and Aptose Biosciences, Inc. (Nasdaq: APTO). Earlier in his career, Greg spent fourteen years in investment banking, including leadership roles as Managing Director and Director of Private Placements at Wedbush Securities, and senior roles at RBC Capital Markets and Wells Fargo Securities.

Greg holds an M.B.A. in Finance from The Wharton School at the University of Pennsylvania and a B.A. in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara. Greg is also a Certified Public Accountant (inactive) in the State of California.

What is Gregory K. Chow's net worth?: The estimated net worth of Gregory K. Chow is at least $67.84 thousand as of October 15th, 2025. Mr. Chow owns 1,975 shares of Sutro Biopharma stock worth more than $67,841 as of April 22nd. This net worth approximation does not reflect any other assets that Mr. Chow may own. Learn More about Gregory K. Chow's net worth.
How do I contact Gregory K. Chow?: The corporate mailing address for Mr. Chow and other Sutro Biopharma executives is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. Sutro Biopharma can also be reached via phone at (650) 392-8412 and via email at [email protected]. Learn More on Gregory K. Chow's contact information.
Has Gregory K. Chow been buying or selling shares of Sutro Biopharma?: Gregory K. Chow has not been actively trading shares of Sutro Biopharma in the last ninety days. Most recently, on Wednesday, October 15th, Gregory K. Chow bought 1,975 shares of Sutro Biopharma stock. The stock was acquired at an average cost of $8.10 per share, with a total value of $15,997.50. Following the completion of the transaction, the chief financial officer now directly owns 1,975 shares of the company's stock, valued at $15,997.50. Learn More on Gregory K. Chow's trading history.
Who are Sutro Biopharma's active insiders?: Sutro Biopharma's insider roster includes Gregory Chow (Chief Financial Officer), Connie Matsui (Director), David Pauling (Insider), and Nicki Vasquez (Insider). Learn More on Sutro Biopharma's active insiders.
Are insiders buying or selling shares of Sutro Biopharma?: During the last year, Sutro Biopharma insiders bought shares 5 times. They purchased a total of 11,175 shares worth more than $89,597.50. The most recent insider tranaction occured on October, 15th when insider Hans-Peter Gerber bought 1,700 shares worth more than $13,600.00. Insiders at Sutro Biopharma own 5.9% of the company. Learn More about insider trades at Sutro Biopharma.
Information on this page was last updated on 10/15/2025.

Gregory K. Chow Insider Trading History at Sutro Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/15/2025	Buy	1,975	$8.10	$15,997.50	1,975

Gregory K. Chow Buying and Selling Activity at Sutro Biopharma

Sutro Biopharma Company Overview

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Today's Range

Now: $34.35

$33.61

$35.40

50 Day Range

MA: $23.20

$15.62

$34.58

2 Week Range

Now: $34.35

$5.60

$35.40

Volume

192,597 shs

Average Volume

227,505 shs

Market Capitalization

$569.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31